What pneumococcal vaccines are currently available and what are the recommended dosing schedules for various age and risk groups?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Available Pneumococcal Vaccines

Four pneumococcal vaccines are currently licensed and available in the United States: PPSV23 (Pneumovax23), PCV13 (Prevnar13), PCV15 (Vaxneuvance), and PCV20 (Prevnar20), with PCV21 (CAPVAXIVE) recently added as a fifth option. 1

Currently Licensed Vaccines

Pneumococcal Conjugate Vaccines (PCVs)

  • PCV13 (Prevnar13, Pfizer) - Licensed 2011

    • Covers 13 serotypes
    • Approved for ages ≥6 weeks through adults
    • Generates robust immune memory through conjugation to CRM197 protein
    • Now primarily used based on shared clinical decision-making in limited scenarios 1

  • PCV15 (Vaxneuvance, Merck) - Licensed 2021

    • Covers 15 serotypes (adds serotypes 22F and 33F to PCV13)
    • Approved for ages ≥6 weeks
    • Must be followed by PPSV23 when used in adults 1

  • PCV20 (Prevnar20, Pfizer) - Licensed 2021

    • Covers 20 serotypes (adds 7 additional serotypes beyond PCV13)
    • Approved for ages ≥6 weeks through adults
    • Can be used as single-dose regimen without need for PPSV23 1

  • PCV21 (CAPVAXIVE, Merck) - Recently approved

    • Covers 21 serotypes
    • Alternative single-dose option for adults
    • Note: In western US, serotypes not in PCV21 cause >30% of IPD cases, making PCV20 preferred in this region 2, 3

Pneumococcal Polysaccharide Vaccine

  • PPSV23 (Pneumovax23, Merck) - Licensed 1983
    • Covers 23 serotypes
    • Approved for ages ≥2 years
    • Does not generate immune memory (T-cell independent response)
    • Requires 1-3 doses depending on age and risk factors 1

Current Dosing Recommendations by Age and Risk Group

Adults Aged ≥50 Years (Updated October 2024)

All PCV-naïve adults aged ≥50 years should receive a single dose of PCV (PCV20 or PCV21 preferred). 3

  • Preferred approach: Single dose of PCV20 or PCV21 (no PPSV23 needed)
  • Alternative approach: PCV15 followed by PPSV23 at least 1 year later
  • This represents a significant expansion from the previous age threshold of ≥65 years 3

Adults Aged 19-49 Years with Risk Conditions

Adults with immunocompromising conditions, CSF leak, cochlear implant, chronic heart/lung/liver disease, diabetes, or other risk factors should receive PCV vaccination. 1

  • Same vaccine options as older adults (PCV20/PCV21 alone or PCV15 + PPSV23)
  • Timing and number of PPSV23 doses varies by specific risk condition (1-3 doses total) 1

High-Risk Groups Requiring Special Consideration

Adults with immunocompromising conditions, functional/anatomic asplenia, CSF leak, or cochlear implant require more intensive vaccination schedules. 1

Risk conditions include:

  • Immunocompromising conditions (HIV, malignancy, immunosuppressive therapy, solid organ transplant)
  • Functional or anatomic asplenia
  • Chronic renal failure or nephrotic syndrome
  • CSF leak or cochlear implant
  • Chronic heart, lung, or liver disease
  • Diabetes mellitus

For these patients:

  • Single dose PCV20 or PCV21 is preferred
  • If using PCV15, follow with PPSV23 at least 1 year later
  • May require up to 3 total doses of PPSV23 over lifetime depending on specific condition 1

Previously Vaccinated Adults

Adults who previously received only PCV13 should now receive PCV20 at least 5 years after their last pneumococcal vaccine dose. 1

Adults who received both PCV13 and PPSV23 can receive a single dose of PCV20 at least 5 years after their last dose to expand serotype coverage. 1

Children and Adolescents

  • Routine childhood vaccination: PCV13, PCV15, or PCV20 in 4-dose series at 2,4,6, and 12-15 months 4
  • High-risk children aged 2-18 years: May require PPSV23 in addition to PCV series 4

Key Clinical Considerations

Vaccine Selection Algorithm

  1. For vaccine-naïve adults ≥50 years: Choose PCV20 or PCV21 as single dose (simplest, broadest coverage)
  2. For adults with previous PCV13 only: Add PCV20 after ≥5 years
  3. For adults with PCV13 + PPSV23: Consider PCV20 after ≥5 years for additional serotype coverage
  4. Western US populations: Prefer PCV20 over PCV21 due to regional serotype epidemiology 2

Common Pitfalls to Avoid

  • Do not give PPSV23 before PCV - This reduces the immune response to subsequent PCV administration. Always give PCV first 5
  • Respect minimum intervals - When using PCV15 + PPSV23 strategy, wait at least 1 year between doses (8 weeks minimum for high-risk groups) 5
  • Do not assume all adults are vaccinated - Coverage remains suboptimal despite clear recommendations 6
  • Regional considerations matter - Serotype distribution varies geographically, affecting optimal vaccine choice 2

Simplified Current Approach (2024-2025)

The pneumococcal vaccination landscape has been dramatically simplified: most adults now need only a single dose of PCV20 or PCV21, eliminating the complex sequential regimens of the past. 1, 3

This represents a major shift from previous recommendations that required PCV13 followed by PPSV23 in specific sequences with varying intervals. The newer higher-valency conjugate vaccines provide broader serotype coverage with superior immunogenicity in a single dose, improving both protection and implementation feasibility 1, 7.

References

Related Questions

In a patient who received a pneumococcal vaccine three days ago and experienced transient fever and malaise, how long is a local reaction of redness and soreness at the injection site expected to last?
What are the indications for pneumococcal vaccination in adults, including age thresholds and specific risk factors?
What is the recommended interval and method for administering both Prevnar 20 (20‑valent pneumococcal conjugate vaccine) and CAPVAXIVE (13‑valent pneumococcal conjugate vaccine) in the same adult patient?
What pneumococcal vaccination regimen is recommended for a 54-year-old male with recurrent pneumonia infections?
Which pneumococcal vaccines should be administered to a patient with lung cancer?
What are the drug interactions and monitoring considerations when combining aripiprazole (Abilify) with duloxetine (Cymbalta)?
After a vaginal approach myomectomy performed via hysteroscopy, how much tranexamic acid (TXA) should be administered to control significant postoperative bleeding?
When does oral diltiazem reach steady-state concentrations?
What protection does PCV21 (CAPVAXIVE) provide and which patients should receive it?
What is the most common respiratory viral isolate during the summer in the Philippines?
Is oral intake of clear fluids and light foods safe for a woman in active labor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.